NCT05074134View on ClinicalTrials.gov

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 16, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

July 12, 2022

Conditions
Healthy
Interventions
DRUG

[14C]-TNP-2092

Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi \[14C\]-TNP-2092 administered over 60 minutes (± 10 minutes).

Trial Locations (1)

21201

Pharmaron Clinical Pharmacology Center, Baltimore

All Listed Sponsors
lead

TenNor Therapeutics Limited

INDUSTRY

NCT05074134 - Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092 | Biotech Hunter | Biotech Hunter